



EXPRESS MAIL NO. EV689730755US

PTO/SB/08A (05-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Office of U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
and to a collection of information unless it contains a valid OMB control number.

~~Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.~~

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	09/234,208
		Filing Date	January 20, 1999
		First Named Inventor	Doherty
		Art Unit	1642
		Examiner Name	Anne Holleran
		Attorney Docket Number	49321-1
Sheet	1	of	5

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ²
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
Sue	C111	WO0029609	05-25-2000	Oregon Health Sciences University		
SM	C112	WO0044403	08-03-2000	Oregon Health Sciences University		
	C113	WO0161358	08-23-2001	Oregon Health Sciences University		
SM	C114	WO0214470	02-21-2002	Oregon Health and Science University		
	C115	WO05/016966	02-24-05	Receptor BioLogix, Inc.		

Examiner Signature		Date Considered	10/27/05
-----------------------	---	--------------------	----------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04³. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible.⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. Comments should include any specific name or identification number of the form if applicable. Comments should also identify the source of the burden estimate.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/234,208
(Use as many sheets as necessary)				Filing Date	January 20, 1999
				First Named Inventor	Doherty
				Art Unit	1642
				Examiner Name	Anne Holleran
Sheet	2	of	5	Attorney Docket Number	49321-1

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
<i>SM</i>	C116	BAASNER et al., Reversible tumorigenesis in mice by conditional expression of the HER2/c-erbB2 receptor tyrosine kinase, Oncogene 13(5):901-11, 1996			
	C117	BOWIE et al., Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions, Science 247:1306-1310, 1990			
	C118	BRANDON et al., Estrogen Receptor Gene Expression in Human Uterine Leiomyomata, J. Clin. Endocrinol. Metab. 80(6):1876-1881, 1995			
	C119	BRANDON et al., Progesterone receptor messenger ribonucleic acid and protein are overexpressed in human uterine leiomyomas, Am. J. Obstet. Gynecol. 169(1):78-85, 1993			
	C120	BRODOWICZ et al., Soluble HER-2/neu neutralizes biologic effects of anti-HER-2/new antibody on breast cancer cells <i>in vitro</i> , Int. J. Cancer 73:875-879, 1997			
	C121	BROWN et al., Antibodies against Highly Conserved Sites in the Epidermal Growth Factor Receptor Tyrosine Kinase Domain as Probes for Structure and Function, Biochem 32:4659-4664, 1993			
	C122	BURGESS et al., Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue, J. Cell Biol. 111:2129-2138, 1990			
	C123	CLINTON and BROWN, Generation and Use of Anti-peptide Antibodies Directed against Catalytic Domain of Protein Kinases, Methods in Enzymol. 200:463-474, 1991			
	C124	CLINTON and HUA, Estrogen action in human ovarian cancer, Crit. Rev. Oncol/Hematol. 25:1-9, 1997			
<i>SM</i>	C125	CLINTON et al., Estrogens increase the expression of fibulin-1, an extracellular matrix protein secreted by human ovarian cancer cells, Proc. Natl. Acad. Sci. USA 93:316-320, 1996			

<i>Sue</i>	C126	DERMER, Another Anniversary for the War on Cancer, Bio/Technology 12:320, 1994	
	C127	DI FIORE et al., <i>erbB-2</i> Is a Potent Oncogene When Overexpressed in NIH/3T3 Cells, Science 237:178-182, 1987	
	C128	DILLMAN, Antibodies as Cytotoxic Therapy, J. Clin. Oncol. 12(7):1497-1515, 1994	
	C129	DOHERTY et al., An Alternative HER-2/ <i>neu</i> Transcript of 8 kb Has an Extended 3'UTR and Displays Increased Stability in SKOV-3 Ovarian Carcinoma Cells, Gynecol. Oncol. 74:408-415, 1999	
	C130	DOUGALL et al., The <i>neu</i> -oncogene: signal transduction pathways, transformation mechanisms and evolving therapies, Oncogene 9:2109-2123, 1994	
	C131	GREENSPAN and DI CERA, Defining epitopes: It's not as easy as it seems, Nature Biotechn. 17:936-937, 1999	
	C132	HUA et al., SKOV3 Ovarian Carcinoma Cells Have Functional Estrogen Receptor but are Growth-resistant to Estrogen and antiestrogens, J. Steroid Biochem. Molec. Biol. 55(3/4):279-289, 1995	
	C133	HUDZIAK et al., Increased expression of the putative growth factor receptor p185 ^{HER2} causes transformation and tumorigenesis of NIH 3T3 cells, Proc. Natl. Acad. Sci. USA 84:7159-7163, 1987	
	C134	HYNES and STERN, The biology of <i>erbB-2/neu/HER-2</i> and its role in cancer, Biochimica et Biophysica Acta 1198:165-184, 1994	
	C135	JHABVALA-ROMERO et al., Herstatin inhibits heregulin-mediated breast cancer cell growth and overcomes tamoxifen resistance in breast cancer cells that overexpress HER-2, Oncogene 22:8178-8186, 2003	
	C136	JUSTMAN and CLINTON, Herstatin, an Autoinhibitor of the Human epidermal Growth Factor Receptor 2 Tyrosine Kinase, Modulates Epidermal Growth Factor Signaling Pathways Resulting in Growth Arrest, J. Biol. Chem. 277(23):20618-20624, 2002	
	C137	KERN et al., Inhibition of Human Lung Cancer Cell Line Growth by an Anti-p185 ^{HER2} Antibody, Am. J. Respir. Cell Mol. Biol. 9:448-454, 1993	
	C138	LAZAR et al., Transforming Growth Factor α : Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities, Mol. Cell. Biol. 8(3):1247-1252, 1988	
	C139	LEE and CLINTON, Serum Tyrosine Kinase Activity and Neoplastic Disease, Recent Results Cancer Res. 113:32-40, 1989	
<i>V</i>	C140	LEWIS et al., Differential responses of human tumor cell lines to anti-p185 ^{HER2} monoclonal antibodies, Cancer Immunol. Immunother. 37:255-263, 1993	

Su	C141	LIN and CLINTON, A soluble protein related to the HER-2 proto-oncogene product is released from human breast carcinoma cells, <i>Oncogene</i> 6(4):639-643, 1991	
	C142	LIN and CLINTON, Human prostatic acid phosphatase has phosphotyrosyl protein phosphatase activity, <i>Biochem. J.</i> 235:351-357, 1986	
	C143	LIN and Clinton, The Epidermal Growth Factor Receptor from Prostate Cells Is Dephosphorylated by a Prostate-Specific Phosphotyrosyl Phosphatase, <i>Mol. Cell Biol.</i> 8(12): 5477-5485, 1988	
	C144	LIN et al., Characterization of Tyrosyl Kinase Activity in Human Serum, <i>J. Biol. Chem.</i> 260(3) 1582-1587, 1985	
	C145	LIN et al., Developmental Expression of Tyrosyl Kinase Activity in Human Serum, <i>Human Biol.</i> 59(3):549-556, 1987	
	C146	LIN et al., Disulfide-Linked and Noncovalent Dimers of p185 ^{HER-2} in Human Breast Carcinoma Cells, <i>J. Cell. Biochem.</i> 49:290-295, 1992	
	C147	LIN et al., Insulin and epidermal growth factor stimulate phosphorylation of p185 ^{HER-2} in the breast carcinoma cell line, BT474, <i>Mol. Cell Endocrinol.</i> 69(2-3):111-119, 1990	
	C148	LIN et al., Tyrosyl Kinase Activity is Inversely Related to Prostatic Acid Phosphatase Activity in Two Human Prostate Carcinoma Cell Lines, <i>Mol. Cell Biol.</i> 6(12): 4753-4757, 1986	
	C149	LIU et al., MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an <i>in vitro</i> growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity <i>in vivo</i> , <i>Breast Cancer Res. Treatment</i> 34:97-117, 1995	
	C150	MOLINA et al., NH ₂ -terminal Truncated HER-2 Protein but not Full-Length Receptor is Associated with Nodal Metastasis in Human Breast Cancer, <i>Clin. Cancer Res.</i> 8:347-353, 2002	
	C151	NATALI et al., Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues, <i>Int. J. Cancer</i> 45:457-461, 1990	
	C152	O'ROURKE et al., Trans receptor inhibition of human glioblastoma cells by erbB family ectodomains, <i>Proc. Natl. Acad. Sci. USA</i> 94:3250-3255, 1997	
	C153	PIETRAS et al., HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells, <i>Oncogene</i> 10:2435-2446, 1995	
	C154	SEVERINO et al., Rapid loss of oestrogen and progesterone receptors in human leiomyoma and myometrial explant cultures, <i>Mol. Human Repro.</i> 2(11):823-828, 1996	
	C155	SHAMIEH et al., Receptor binding specificities of Herstatin and its intron 8-encoded domain, <i>FEBS Letters</i> 568:163-166, 2004	

<i>GM</i>	C156	SHEPARD et al., Monoclonal antibody Therapy of Human Cancer: Taking the HER2 Protooncogene to the Clinic, <i>J. Clin. Immunol.</i> 11(3):117-127, 1991	
	C157	STAVEROSKY et al., Herstatin, an autoinhibitor of the epidermal growth factor receptor family, blocks the intracranial growth of glioblastoma, <i>Clin. Cancer Res.</i> 11(1):335-40, 2005	
	C158	TZAHAR et al., Bivalence of EGF-like ligands drives the ErbB signaling network, <i>EMBO Journal</i> 16(16):4938-4950, 1997	
	C159	Uniprot Data base, Database accession No. ERB2_HUMAN, "Receptor tyrosine-protein kinase erbB-2 precursor," 8/13/87, www.ebi.uniprot.org/uniprot-srv/uniProtView.do?proteinID=ERB2_HUMAN&pageOffset=null	
<i>V</i>	C160	XIA et al., Combination of EGFR, HER-2/neu, and HER-3 Is a Stronger Predictor for the Outcome of Oral Squamous Cell Carcinoma Than Any Individual Family Members, <i>Clin. Cancer Res.</i> 5:4164-4174, 1999	

Examiner Signature	<i>[Signature]</i>	Date Considered	<i>10/27/05</i>
--------------------	--------------------	-----------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.